Full Press Release Details
Cellect Biotechnology Continues to Achieve
Milestones; Receives New Patent Allowance in Canada
Tel Aviv, Israel - April 27, 2020
- Cellect Biotechnology Ltd. (NASDAQ: "APOP"), a developer of innovative technology which enables the functional
selection of stem cells, received an official communication from the Canadian Intellectual Property Office regarding its intention
to grant Canadian Patent Application No. 2,866,358 for Apograft. Including this latest notification, the Company has 67 patent
applications worldwide, of which 33 are issued/allowed patents.
"The Canada patent complements those
we recently received in Australia and Israel, for the same claim," commented Dr. Shai Yarkoni, Chief Executive Officer. "I
believe our level of success in the first few months of 2020 demonstrates our continued commitment to protect our innovation, plus
the significance of today's achievement cannot be underestimated since we now have global coverage for our main patent, following
the allowances in the other key markets, such as the US, EU and China. The global coverage allows us to continue building our strong
portfolio where we continue protecting the methods of use, manufacturing and specific applications of our technology."
The Company has previously published third-party
data demonstrating improved "stemness" of stem cells through use of the Company's technology. Specifically, the
data shows that the Company's technology significantly improves both proliferation and functional capabilities of hematopoietic
(HSC) and mesenchymal (MSC) stem cells originating from bone marrow, peripheral blood, umbilical cord and adipose tissue.
The patent covers a device and a kit adapted
for selection of cells that are resistant to receptor-mediated apoptosis and a method for using the device and kit. The device
enables simultaneous positive selection for both stem-cells and immune cells which support engraftment and negative selection for
immune cells which induce graft versus host disease (GvHD). The device is designed as a closed compartment for cell selection in
a simplified setting resulting in a safer, more efficacious and affordable solution that currently do not exist. The Company's
patent applications for this technology discloses additional uses for the device.
The Company is also assessing implementation
of the Apograft process in approved medical devices. Upon completion of the comparability assessment, we intend to move into strategic
collaborations with companies already selling these devices.
About Cellect Biotechnology Ltd.
Cellect Biotechnology (APOP) has developed
a breakthrough technology, for the selection of stem cells from any given tissue, that aims to improve a variety of stem cell-based
The Company's technology is expected
to provide researchers, clinical community and pharma companies with the tools to rapidly isolate stem cells in quantity and quality
allowing stem cell-based treatments and procedures in a wide variety of applications in regenerative medicine. The Company's
current clinical trial is aimed at bone marrow transplantations in cancer treatment.
Forward Looking Statements
This press release contains forward-looking
statements about the Company's expectations, beliefs and intentions. Forward-looking statements can be identified by the
use of forward-looking words such as "believe", "expect", "intend", "plan", "may",
"should", "could", "might", "seek", "target", "will", "project",
"forecast", "continue" or "anticipate" or their negatives or variations of these words or other
comparable words or by the fact that these statements do not relate strictly to historical matters. These forward-looking statements
and their implications are based on the current expectations of the management of the Company only and are subject to a number
of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.
In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results
would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional
research or otherwise. The following factors, among others, could cause actual results to differ materially from those described
in the forward-looking statements: the Company's history of losses and needs for additional capital to fund its operations
and its inability to obtain additional capital on acceptable terms, or at all; the Company's ability to continue as a going
concern; uncertainties of cash flows and inability to meet working capital needs; the Company's ability to obtain regulatory
approvals; the Company's ability to obtain favorable pre-clinical and clinical trial results; the Company's technology
may not be validated and its methods may not be accepted by the scientific community; difficulties enrolling patients in the Company's
clinical trials; the ability to timely source adequate supply of FasL; risks resulting from unforeseen side effects; the Company's
ability to establish and maintain strategic partnerships and other corporate collaborations; the scope of protection the Company
is able to establish and maintain for intellectual property rights and its ability to operate its business without infringing the
intellectual property rights of others; competitive companies, technologies and the Company's industry; unforeseen scientific
difficulties may develop with the Company's technology; and the Company's ability to retain or attract key employees
whose knowledge is essential to the development of its products. Any forward-looking statement in this press release speaks only
as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement,
whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities
laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk
Factors" in Cellect Biotechnology Ltd.'s Annual Report on Form 20-F for the fiscal year ended December 31, 2019 filed
with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC's website, www.sec.gov, and in the
Company's periodic filings with the SEC.
Cellect Biotechnology Ltd.
Eyal Leibovitz, Chief Financial Officer